← back to search

Andrea Farolfi

University of California, Los Angeles · US
Area of research
Pulmonary and Respiratory Medicine · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications, and Medical Imaging Techniques and Applications.
h-index
26
citations
3,922
works
199
NIH funding
primary concept
email

Recent publications

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study
European Urology 2025cited by 23position: middledoi
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent
European Urology 2024cited by 1,013position: middledoi
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer
European Urology 2024cited by 297position: middledoi
RECIP 1.0 Predicts Progression-Free Survival After [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Journal of Nuclear Medicine 2024cited by 22position: middledoi
European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy
Radiotherapy and Oncology 2024cited by 8position: middledoi
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer
Radiology 2023cited by 98position: lastdoi
PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to [<sup>177</sup>Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study
Journal of Nuclear Medicine 2023cited by 51position: middledoi
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer
JAMA Network Open 2023cited by 30position: middledoi
Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review
European Urology 2023cited by 26position: middledoi
The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy
European Journal of Nuclear Medicine and Molecular Imaging 2023cited by 23position: middledoi
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA &lt; 0.2 ng/ml
European Journal of Nuclear Medicine and Molecular Imaging 2023cited by 20position: middledoi
Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study
Radiotherapy and Oncology 2023cited by 20position: middledoi
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy
European Journal of Nuclear Medicine and Molecular Imaging 2023cited by 12position: middledoi
<sup>68</sup>Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
Journal of Nuclear Medicine 2023cited by 8position: middledoi
Non-oncologic incidental uptake on FAPI PET/CT imaging
British Journal of Radiology 2022cited by 93position: middledoi
PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature
Cancers 2022cited by 39position: middledoi
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy
International Journal of Radiation Oncology*Biology*Physics 2022cited by 31position: middledoi
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis
European Journal of Nuclear Medicine and Molecular Imaging 2022cited by 30position: middledoi
Diagnostic Accuracy of <sup>68</sup>Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection
JAMA Oncology 2021cited by 335position: middledoi
Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis
European Urology Focus 2021cited by 62position: middledoi
<sup>68</sup> Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study
The Journal of Urology 2019cited by 41position: firstdoi
Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET
Journal of Nuclear Medicine 2019cited by 26position: firstdoi
68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA &lt;0.5 ng/ml. Efficacy and impact on treatment strategy
European Journal of Nuclear Medicine and Molecular Imaging 2018cited by 137position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Jérémie Calais · Dana-Farber Cancer Institute7 papers (2019–2024)Wolfgang P. Fendler · Molecular Theranostics (United States)7 papers (2019–2024)Ken Herrmann · Indiana University – Purdue University Indianapolis6 papers (2019–2024)Matthias Eiber · German Cancer Research Center6 papers (2019–2024)Andrei Gafita · UCLA Health5 papers (2019–2024)Manuel Weber · Fraunhofer Institute for Material Flow and Logistics4 papers (2019–2024)Stefano Fanti · European Institute of Oncology4 papers (2018–2023)Matthias Benz · University of California, Los Angeles4 papers (2022–2024)Boris Hadaschik · Deutsche Gesellschaft für Urologie4 papers (2019–2024)Francesco Barbato · German Cancer Research Center3 papers (2019–2021)Louise Emmett · Sydney Hospital3 papers (2023–2024)Thomas A. Hope · UCSF Helen Diller Family Comprehensive Cancer Center3 papers (2021–2023) · 2 papers (2019–2019)Johannes Czernin · Molecular Theranostics (United States)2 papers (2021–2023) · 2 papers (2019–2019)Fabian Spohn · Heidelberg University2 papers (2019–2019)Harun Ilhan · Ludwig-Maximilians-Universität München2 papers (2019–2019)Uwe Haberkorn · Heidelberg University2 papers (2019–2019) · 2 papers (2018–2023)Sarah M. Schwarzenböck · Technical University of Munich2 papers (2021–2023)